Cargando…

The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification

BACKGROUND: Chuanxiong Rhizoma (CR) is a common traditional Chinese medicine (TCM) that has been widely used in the treatment of spinal cord injury (SCI). However, the underlying molecular mechanism of CR is still largely unknown. This study was designed to explore the bioactive components and the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Bo, Wang, Qi, Cao, Jiangang, Yasen, Yimingjiang, Ma, Lei, Sun, Chao, Shang, Jun, Feng, Shiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350674/
https://www.ncbi.nlm.nih.gov/pubmed/34430586
http://dx.doi.org/10.21037/atm-21-2529
_version_ 1783735819439177728
author Tao, Bo
Wang, Qi
Cao, Jiangang
Yasen, Yimingjiang
Ma, Lei
Sun, Chao
Shang, Jun
Feng, Shiqing
author_facet Tao, Bo
Wang, Qi
Cao, Jiangang
Yasen, Yimingjiang
Ma, Lei
Sun, Chao
Shang, Jun
Feng, Shiqing
author_sort Tao, Bo
collection PubMed
description BACKGROUND: Chuanxiong Rhizoma (CR) is a common traditional Chinese medicine (TCM) that has been widely used in the treatment of spinal cord injury (SCI). However, the underlying molecular mechanism of CR is still largely unknown. This study was designed to explore the bioactive components and the mechanism of CR in treating SCI based on a network pharmacology approach and experimental validation. METHODS: First, the active compounds and related target genes in CR were screened from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Subsequently, the corresponding target genes of SCI were collected by the Therapeutic Target Database (TTD) and GeneCards database. A protein-protein interaction (PPI) network was constructed using the STRING database. Furthermore, GO function and KEGG enrichment analysis of the targets were analyzed using DAVID tools. Subsequently, the AutoDock software for molecular docking was adopted to verify the above network pharmacology analysis results between the active components and key targets. Finally, an SCI rat model animal validation experiment was assessed to verify the reliability of the network pharmacology results. RESULTS: There were 7 active ingredients identified in CR and 246 SCI-related targets were collected. Then, 4 core nodes (ALB, AKT1, MAPK1, and EGFR) were discerned via construction of a PPI network of 111 common targets. The KEGG enrichment analysis results indicated that the Ras signaling pathway, estrogen signaling pathway, and vascular endothelial growth factor (VEGF) signaling pathway were enriched in the development of SCI. The results of molecular docking demonstrated that the effects of CR have a strong affinity with the 4 pivotal targets. Experimental validation in a rat model showed that CR could effectively improve the recovery of motor function and mechanical pain threshold after SCI. CONCLUSIONS: In summary, it revealed the mechanism of CR treatment for SCI involve active ingredients, targets and signaling pathways, providing a scientific basis for future investigations into the mechanism underlying CR treating for SCI.
format Online
Article
Text
id pubmed-8350674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-83506742021-08-23 The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification Tao, Bo Wang, Qi Cao, Jiangang Yasen, Yimingjiang Ma, Lei Sun, Chao Shang, Jun Feng, Shiqing Ann Transl Med Original Article BACKGROUND: Chuanxiong Rhizoma (CR) is a common traditional Chinese medicine (TCM) that has been widely used in the treatment of spinal cord injury (SCI). However, the underlying molecular mechanism of CR is still largely unknown. This study was designed to explore the bioactive components and the mechanism of CR in treating SCI based on a network pharmacology approach and experimental validation. METHODS: First, the active compounds and related target genes in CR were screened from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Subsequently, the corresponding target genes of SCI were collected by the Therapeutic Target Database (TTD) and GeneCards database. A protein-protein interaction (PPI) network was constructed using the STRING database. Furthermore, GO function and KEGG enrichment analysis of the targets were analyzed using DAVID tools. Subsequently, the AutoDock software for molecular docking was adopted to verify the above network pharmacology analysis results between the active components and key targets. Finally, an SCI rat model animal validation experiment was assessed to verify the reliability of the network pharmacology results. RESULTS: There were 7 active ingredients identified in CR and 246 SCI-related targets were collected. Then, 4 core nodes (ALB, AKT1, MAPK1, and EGFR) were discerned via construction of a PPI network of 111 common targets. The KEGG enrichment analysis results indicated that the Ras signaling pathway, estrogen signaling pathway, and vascular endothelial growth factor (VEGF) signaling pathway were enriched in the development of SCI. The results of molecular docking demonstrated that the effects of CR have a strong affinity with the 4 pivotal targets. Experimental validation in a rat model showed that CR could effectively improve the recovery of motor function and mechanical pain threshold after SCI. CONCLUSIONS: In summary, it revealed the mechanism of CR treatment for SCI involve active ingredients, targets and signaling pathways, providing a scientific basis for future investigations into the mechanism underlying CR treating for SCI. AME Publishing Company 2021-07 /pmc/articles/PMC8350674/ /pubmed/34430586 http://dx.doi.org/10.21037/atm-21-2529 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Tao, Bo
Wang, Qi
Cao, Jiangang
Yasen, Yimingjiang
Ma, Lei
Sun, Chao
Shang, Jun
Feng, Shiqing
The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
title The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
title_full The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
title_fullStr The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
title_full_unstemmed The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
title_short The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
title_sort mechanisms of chuanxiong rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350674/
https://www.ncbi.nlm.nih.gov/pubmed/34430586
http://dx.doi.org/10.21037/atm-21-2529
work_keys_str_mv AT taobo themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT wangqi themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT caojiangang themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT yasenyimingjiang themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT malei themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT sunchao themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT shangjun themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT fengshiqing themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT taobo mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT wangqi mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT caojiangang mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT yasenyimingjiang mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT malei mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT sunchao mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT shangjun mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification
AT fengshiqing mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification